Nonanticoagulant Actions of Glycosaminoglycans

1. Front Matter

   Pages i-viii

   PDF

2. Inequivalence of Glycosaminoglycans Using High-Performance Size Exclusion Chromatography, Polyacrylamide Gel Electrophoresis and High-Performance Capillary Electrophoresis

   • Reinhard Malsch, Job Harenberg, Lukas Piazolo, Dieter L. Heene

   Pages 1-14

3. New NMR Spectroscopic Approaches for Structural Analysis of Glycosaminoglycans

   • Giangiacomo Torri

   Pages 15-25

4. Application of Mass Spectrometry to the Analysis of Natural and Synthetic Sulfated Oligosaccharides

   • Luigi Silvestro, Simona Rizea Savu, P. A. van Veelen, P. L. Jacobs

   Pages 27-46

5. Monoclonal Antibody Directed Against Heparin and Heparin-Fractions

   • Günter Huhle, Job Harenberg, Reinhard Malsch, Dieter L. Heene

   Pages 47-58

6. Simulation of Glycosaminoglycan Structures by Chemical Modifications of E. Coli Polysaccharides K5 and K4

   • Annamaria Naggi

   Pages 59-64

7. Pharmacology of Synthetic and Biotechnology-Derived Homologues and Analogues of Heparin

   • Walter Jeske, Jawed Fareed, Debra Hoppensteadt, Benito Casu

   Pages 65-87

8. Protein Binding of Sulfated Glycosaminoglycans

   • Benito Casu

   Pages 89-99

9. Non-Anticoagulant Actions of Glycosaminoglycans

   • Alfonso Iorio, Adriano Alatri, Giancarlo Agnelli

   Pages 101-112

10. Binding of Glycosaminoglycans to Leukocytes Using Fluorescent Labeled Gag-Derivatives

    • Job Harenberg, Reinhard Malsch, Lukas Piazolo, Günter Huhle, Dieter L. Heene

    Pages 113-126

11. Intact Biological Activity and Binding to Granulocytes of LMM-Heparin-Tyramine-Fitc

    • Lukas Piazolo, Job Harenberg, Reinhard Malsch, Dieter L. Heene

    Pages 127-138

12. A Detailed Evaluation of the Structural and Biological Effects of Alkaline O-Desulfation Reactions of Heparin

    • Kevin R. Holme, Weisheng Liang, Zicheng Yang, France Lapierre, Patrick N. Shaklee, Lun Lam

    Pages 139-162

13. Glycosaminoglycans and Related Structures as Potential Inhibitors for Erythrocyte Infection by Plasmodium Falciparum Malaria

    • Roger A. Laine

    Pages 163-170

14. The Interaction of Basic Fibroblast Growth Factor (bFGF) With Heparan Sulfate Proteoglycans

    • Marco Rusnati, D. Coltrini, Pasqua Oreste, Giorgio Zoppetti, Marco Presta

    Pages 171-187

15. Binding of 125I-bFGF to Rat Aortic Smooth Muscle Cells

    • Laura Giorgini, Annamaria Naggi, Giancarlo Ghiselli

    Pages 189-199

16. Modulatory Role of Heparin and Heparan Sulfates on Angiogenesis

    • Giovanni Camussi, E. Battaglia, Enrico Lupia, G. Montrucchio

    Pages 201-208

17. Involvement of Thrombin on Gags Release in Different Cellular Systems

    • Domenico Rotilio, Antonio Tamburro, B. Mariani, O. Lancia, Francesco Peracchia

    Pages 209-225

18. TFPI Release by GAGs and Its Role in Their Mechanism of Action

    • Piotr Radziwon, J. Schenk, B. Boczkowska-Radziwon, Jawed Fareed, Hans K. Breddin

    Pages 227-233

19. Biological Activities and Effects on the Platelet Aggregation of a Structurally Defined Curdlan Sulfate

    • Susanne Alban, Walter Jeske, Debra Hoppensteadt, Jawed Fareed, Gerhard Franz

    Pages 235-242

20. Influence of Glycosaminoglycans on Natural Killer Cell Activity

    • Sabine Johann, Reinhold Förster

    Pages 243-248

Prophylaxis and treatment of thromboembolism have made one of the major impacts in medicine. Heparin has widely been used as the most effective drug during the last 50 years. However, its potential side effects have led to the search for equally effective but safer alternatives. At present, the low-molecular-weight heparins are the most promising steps in this direction. Considerable interest has been generated at the same time in exploring other gly­ cosaminoglycans of the nonheparin type for therapeutic use. The existence of these com­ pounds has been known for a long time and substantial information has been gathered on glycosaminoglycans such as heparinsulfate, dermatansulfate, and chondroitinsulfate. Many of these substances are derived from animal or plant sources, and some of them have now been synthesized. The aim of the Fourth Symposium on Glycosaminoglycan Research at Villa Vigoni in Loveno at Lake Comolltaly was to summarize the considerable new information in this field. The articles of the present volume are mainly based on a German-Italian collaboration supported by the Vigoni Program. The selected articles describe many different, nonheparin glycosaminoglycans, some of them already in clinical trials as antithrombotic agents. In particular, the interaction of glycosaminoglycans with some cellular elements of blood, especially leukocytes and platelets, are discussed. New methods for their identification and assays are described and considerable emphasis is placed on the pharmacokinetic aspects of these new compounds. Particularly, some nonanticoagulant activities of the glycosamino­ glycans are discussed in detail.

• Alzheimer
• Oligosaccharid
• biotechnology
• clinical trial
• drug
• pharmacology
• protein
• research

• University of Heidelberg, Mannheim, Germany

  Job Harenberg

• G. Ronzoni Institute, Milan, Italy

  Benito Casu

Policies and ethics